GlassScriptPhysician profile
Inna Kleyman
NPI 1912227760
$1,725.19
in general payments reported to CMS, 2019-2025
15 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $48.41 · 2021: $49.18 · 2022: $351 · 2023: $158 · 2024: $230 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $495.23 | 2022-2025 | |
| Allergan, INC. | $248.04 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $163.47 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Supernus Pharmaceuticals, INC. | $141.77 | 2019 | |
| Csl Behring | $111.99 | 2019 | |
| Emd Serono, INC. | $90.39 | 2019 | |
| Eisai INC. | $76.49 | 2025 | |
| Pfizer INC. | $73.60 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $62.12 | 2019 | |
| Grifols USA, LLC | $23.52 | 2023 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $20.75 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.04 | 2019 | |
| Strongbridge US INC. | $16.62 | 2019 | |
| Lundbeck LLC | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Kleyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.